AnnoHEM blood cancer gene test

Hematological malignancies are a class of highly heterogeneous diseases, and their diagnosis and treatment require a comprehensive analysis of morphology, immunology, genetics, and molecular biology. Next-generation sequencing (NGS), as a new molecular biology technology, has the advantages of high throughput, high sensitivity, and low cost. It is an important means to explore the molecular pathogenesis of hematological malignancies and guide clinical diagnosis and treatment. The rapid development of high-throughput gene sequencing technology and molecular diagnostic technology has provided a theoretical basis for the classification, risk stratification, and treatment of hematological malignancies, greatly promoted the development of targeted therapy, immunotherapy, cell therapy, and hematopoietic stem cell transplantation, and achieved good clinical application results.
AnnoHEM, a high-throughput sequencing series of blood tumor gene detection products independently developed by Baiyang Biodiagnostics, has core detection genes mainly based on the blood system disease diagnosis and treatment guidelines or expert consensus issued by the Chinese Anti-Cancer Association, Chinese Medical Association, WHO, NCCN and other institutions, as well as important genes and tumor susceptibility germline genes reported in other authoritative literature, and are customized after optimization and verification.
AnnoHEM series products mainly include mutation version, fusion version and panoramic version. The mutation version includes 627 hotspot genes related to blood tumors, providing blood tumor patients with comprehensive analysis of clinically significant gene mutations, fusions, TMB, HLA typing and tumor neoantigen prediction, covering the diagnosis and typing of blood tumors, treatment guidance, prognosis assessment, genetic susceptibility and recurrence monitoring (MRD) and other diagnosis and treatment processes; the fusion version (RNA-seq) can be tested once and report a series of key results such as fusion genes, gene mutations, chromosome copy number variations, etc.; the panoramic version is a powerful combination of the mutation version and the fusion version, which provides strong support for doctors to formulate more accurate and personalized treatment plans and prognosis assessments.

Sample requirements